OPTN News and Press, OptiNose Inc. From 11/16/21

Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...

Gainers: Kezar Life Sciences KZR +36%, Progenity (NASDAQ:PROG) +28%, GeoVax Labs GOVX +15%, Medicenna Therapeutics (NASDAQ:MDNA) +15%, Amarin AMRN +10%. Losers: Talkspace TALK -37%, OptiNose OPTN -34%, Molecular Partners MOLN&#x...

Optinose (NASDAQ:OPTN) intends to offer and sell its common shares in a public offering. Shares are down 26.8% premarket at $1.75. Underwriters' over-allotment is an an additional 15% of shares. Price and other terms have not yet been determined. Net proceeds will be used for workin...

OptiNose (NASDAQ:OPTN): Q3 GAAP EPS of -$0.32 beats by $0.04. Revenue of $21.83M (+41.4% Y/Y) misses by $1.65M. Press Release For further details see: OptiNose EPS beats by $0.04, misses on revenue

Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and webcast to be held tomorrow at 8:30 a.m. Eastern Time YARDLEY, Pa., N...

Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announce...

Company Expects Top-Line Results in Second Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis Sufferers in the U.S. YARDLEY, Pa, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Optinose...

According to OptiNose's management, in 2021, the company's revenue will be at least $80 million, which is 62.9% more than in 2020. The company's gross margin is around 87%, well above the pharmaceutical industry average. Xhance sales increased 78.6% in Q2 2021 compared to Q2 2020....

OptiNose, Inc. (OPTN) Q2 2021 Earnings Conference Call August 11, 2021, 11:00 ET Company Participants Jonathan Neely - VP, IR & Business Operations Peter Miller - CEO & Director Keith Goldan - CFO Ramy Mahmoud - President & COO Conference Call Participants Brandon Folkes - Cantor ...

The following slide deck was published by OptiNose, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: OptiNose, Inc. 2021 Q2 - Results - Earnings Call Presentation